Drug Trial Radar · NCT03682692
ACEI/CCB Versus ACEI/DIU Combination Antihypertensive Therapy in Chinese Hypertensive Patients (ACvAD)
Last checked: Nov 19, 2026Latest source record: Feb 14, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
560
Actual
Start
Jun 1, 2018
Primary completion
Jun 30, 2021
Study completion Mar 31, 2022
Sponsor
- Lead sponsor
- Shanghai Jiao Tong University School of MedicineAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Sep 25, 2018
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (participant)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
1. Study name: ACEI/CCB versus ACEI/DIU combination antihypertensive therapy in Chinese hypertensive patients (ACvAD) 2. Rationale:Most current hypertension guidelines recommend the combination therapy of an angiotensin-converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARB) with a calcium antagonists (CCB) or thiazide diuretics (DIU). However, whether the two combination treatments have similar antihypertensive effects in Chinese hypertensive patients is still lack of clinical evidence, especially randomized controlled trials using ambulatory or home blood pressure measurement as the main evaluation method. 3. Study design: This study is a multi-center, randomized and controlled clinical trial with two equally sized treatment groups: ACEI/CCB group and ACEI/DIU group. 4. Study population: Men or women over 18 years (n=580) meeting the inclusion/exclusion criteria. 5. Randomization and treatment: Potentially eligible patients should receive a 24-hour ambulatory blood pressure monitoring measurement before randomization. After stratification by centers and whether receive antihypertensive treatment, eligible patients will be randomly divided into two groups, taking benazepril 10 mg/amlodipine besylate 5mg fixed-dose combination (1 tablet once a day) or benazepril 10 mg/hydrochlorothiazide 12.5 mg fixed-dose combination (1 tablet once a day). 6. Follow up: All patients should sign an informed consent form before entering the study. The follow-up period is 6 months. 7. Sample size estimation: a total of 580 patients should be enrolled in this study.
Conditions
- Hypertension
Interventions
ACEI/CCBDrug
benazepril 10 mg / amlodipine besylate 5 mg fixed-dose combination
ACEI/DIUDrug
benazepril 10 mg / hydrochlorothiazide 12.5 mg fixed-dose combination
Primary outcomes
What the sponsor says the trial is designed to measure.
- 24-hour ambulatory systolic blood pressure reductionTime frame: 6 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Shanghai Institite of Hypertension, Ruijin Hospital, Shanghai Jiaotong University School of Medicine
Shanghai, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.